AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06144983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: in the second group (1ml) of Periokin (Kin Inc., Spain), containing 0.2% Chlorhexidine bioadhesive gel was injected to fill the entire socket
Study NCT04934787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENMS-BSF assisted gait training
Description: 1. ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~2. Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~3. In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane.
Study NCT04934787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENMS-BSF assisted gait training
Description: 1. ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~2. Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~3. In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane.
Study NCT04934787 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ENMS-BSF assisted gait training
Description: 1. ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~2. Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~3. In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane.
Study NCT05855447 — intervention group
Intervention type: OTHER
Intervention: NIRS device usage during 6MWT
Description: It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
Study NCT05855447 — intervention group
Intervention type: OTHER
Intervention: Peripheral Muscle Strength Measurement
Description: The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
Study NCT05855447 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
Study NCT06548906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4 Injection
Description: GZR4 Injection administered sc, once weekly.
Study NCT05196854 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 1. Standard Home Blood Pressure Measurement
Description: Measurement of Blood Pressure using Home blood pressure monitor
Study NCT05196854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2. Hypnosis script prior to home blood pressure measurement
Description: Pre-recorded clinical hypnosis script (approx 5 mins long) used prior to standard home blood pressure measurement. Clinical Hypnosis is used as a non-pharmacological technique for reducing procedural anxiety, distress and discomfort with patients.
Study NCT06176937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Alveolar ridge preservation by atraumatic tooth extraction and socket curettage then application hyaluronic acid gel after extraction and covering the socket by collagen membrane.
Study NCT06176937 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: empty socket
Description: Alveolar ridge preservation by atraumatic tooth socket without application any drug but just covering the socket by collagen membrane.
Study NCT06240390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous neuromodulation (NMP)
Description: Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
Study NCT05512533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear Ultrasound Bronchoscope BF-UC290F (Olympus)
Description: A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).
Study NCT04943705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yin and Yang Regulating Moxibustion
Description: Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
Study NCT04943705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yin and Yang Regulating Moxibustion
Description: Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
Study NCT06211231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally delivered mindfulness- and acceptance-based psychological intervention
Description: MY-ENDO is developed specifically for endometriosis and includes ten themes; one for each session: 1) endometriosis, 2) chronic pain and pain mechanisms, 3) stress, 4) thoughts and feelings, 5) grief, 6) identity and meaning, 7) everyday life and relations, 8) health, diet and exercise, 9) value-based action and 10) a good life with endometriosis.
Study NCT06240390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pharmacological treatment by Opioids
Description: Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
Study NCT04786119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORI Robotics
Description: Knee arthroplasty with robotics assisted surgery using the CORI Robotics System.
Study NCT05124184 — intervention group
Intervention type: DEVICE
Intervention: GORE® PROPATEN® Vascular Graft
Description: Patients that have had treatment with GORE® PROPATEN® Vascular Graft
Study NCT04992728 — intervention group
Intervention type: OTHER
Intervention: Restricted Spectrum Magnetic Resonance Imagining
Description: Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
Study NCT05124184 — intervention group
Intervention type: DEVICE
Intervention: GORE-TEX® Vascular Grafts
Description: Patients that have had treatment with GORE-TEX® Vascular Grafts
Study NCT04926974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Smart phone App
Study NCT06445868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention
Description: COM-B-based development of specific sedentary behavioral interventions to reduce sedentary time, promote healthy activity, and improve quality of life in older stroke patients
Study NCT06151171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day.
Study NCT06151171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day.
Study NCT03698006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Tibial nerve block with 10ml of Ropivacaine 0.5%
Study NCT03698006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
Study NCT01104844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Dose Strength
Description: Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
Study NCT01104844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quarter dose strength
Description: Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
Study NCT01104844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Half dose strength
Description: Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
Study NCT01104844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen standard dose
Description: Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
Study NCT01104844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen low dose
Description: Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
Study NCT01104844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen high dose
Description: Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
Study NCT01104844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets
Study NCT05944796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diathermy
Description: The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)
Study NCT05944796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)
Study NCT05409391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Titration System
Description: A noval insulin titration system, which is based on deep learning
Study NCT05939167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).
Study NCT05939167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline is used as placebo in the placebo comparator group
Study NCT04799990 — intervention group
Intervention type: DRUG
Intervention: Risankizumab
Description: Subcutaneous Injection
Study NCT04799990 — intervention group
Intervention type: BIOLOGICAL
Intervention: Comparator 1
Description: Subcutaneous or Intravenous Injection
Study NCT04799990 — intervention group
Intervention type: DRUG
Intervention: Comparator 2
Description: Oral, Opthalmic, Subcutaneous or Intravenous Injection
Study NCT06265025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM103 (Part A)
Description: dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days \[2 weeks\]).
Study NCT06265025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM103 (Part B)
Description: dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease \[HNC, CRC\]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days \[2 weeks\]).
Study NCT06265025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM103 and Pembrolizumab (Part C)
Description: dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days \[3 weeks\]).
Study NCT04816812 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.
Study NCT04816812 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle - online lesson intervention
Description: The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
Study NCT04834531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhuli capsule
Description: This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
Study NCT04834531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
Study NCT04834531 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~1. if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~2. if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks.
Study NCT04834531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~1. if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~2. if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks.
Study NCT05090839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Emotional Disclosure (WED)
Description: Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
Study NCT05090839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Emotional Disclosure (WED)
Description: Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
Study NCT04977180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardioprotection
Description: Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
Study NCT05196945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan fumarate + amoxicillin
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral
Study NCT05196945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate
Description: Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
Study NCT04882891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimyo
Description: Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Study NCT04522674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma
Description: 0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
Study NCT05336071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS068 injection
Description: Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
Study NCT05336071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS068 injection
Description: Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
Study NCT04947488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bioarginina C
Description: Dietary supplement vials